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Abstract Fibrinogen y-chain C-terminal peptide HHLG- 
GAKQAGDV (~12) and a-chain peptide GRGDSP are known 
to inhibit fibrinogen-mediated platelet cell aggregation via com- 
petitive interactions with platelet integrin receptor GPIIb/IIIa. 
NMR studies of ~12 in the presence of purified GPIIblIIIa in 
SDS/water solution have demonstrated the presence of two 712 
binding states, one of which is eliminated by GRGDSP (RGD) 
up to a RGD:y12 ratio of 2: 1. RGD:y12 ratios greater than 2: 1 
produce multiple sets of 712 NMR signals in TOCSY spectra. 
At a ratio of 4: 1, two to four such resonance sets can be resolved 
for A405 Q407, A408, G409, D410 and V411 spin systems. The 
number of multiple resonances remains unchanged at ratios of 
6: 1 and 8: 1. Addition of ~12 to reverse the ratio to 8: 8 
(1: 1) has no apparent effect on the RGD-induced distribution. 
Results suggest that RGD irreversibly induces a conformational 
transition(s) in GPIIblIIIa to produce multiple ~12 binding sites 
on the receptor. 
Key words: Fibrinogen; Peptide; Platelet; lntegrin GPlIb/Illa; 
NMR spectroscopy 
1. Introduction 
Integrins are cell surface glycoprotein (GP) receptors that 
mediate cell<ell and extracellular matrixxell adhesion proc- 
esses [ 171. Platelets are known to contain five integrins of which 
GPcl,,,B, (GPIIb/IIIa) is the major constituent [17]. In the 
blood clotting cascade (see review [8]), activated platelets ad- 
here to each other via a bridge which is formed when plasma 
fibrinogen (a 330,000 dalton dimer of three polypeptide chains, 
i.e. a, /3, and y [9]) binds to GPlIb/IIla receptors from different 
platelet cells [3,30]. In fibrinogen, two RGD-containing binding 
sites [29] are located on the a-chain, and one non-RGD site is 
located within the y-chain C-terminal residues 400411, 
HHLGGAKQAGDV (~12) [l&19]. 
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Integrin GPlIb/IlIa, however, is a promiscuous receptor 
which will bind to a wide variety of RGD containing proteins 
(e.g. fibrinogen [18], fibronectin [16,25], vitronectin [26], and 
von Willebrand factor [27]) as well as to the fibrinogen y-chain 
C-terminal sequence. Three ligand binding sites so far have 
been identified on GPIIb/IIIa: two RGD binding sites on the 
P,-chain (IIIa): residues 119-130 [1,28,31,32] and residues 21 l- 
222 [2,7,20] and one ~12 binding site on the a,,,-chain (IIb): 
residues 294-3 14 [ IO,1 ,12,34]. Other potential RGD interac- 
tive sites have been identified by hydropathy complimentary 
approaches and by monoclonal antibody mapping [4,5,14]. 
Short, linear RGD-containing peptides as well as the fibrin- 
ogen y-chain C-terminal dodecapeptide ~12, can compete with 
parent fibrinogen for GPIIb/IlIa binding and, depending on the 
peptide concentration, even activate GPIIblIIIa-fibrinogen 
binding [13]. Peptide-induced receptor in vitro activation is 
associated with conformational changes on GPlIb/lIIa [ 131. In 
several studies, it has been hypothesized that fibrinogen binding 
to GPIlb/lIIa may proceed by initial recognition of an RGD- 
like sequence, recognition-induced conformational change, and 
then additional high affinity ligand-receptor interaction(s). 
Previous NMR studies of ~12 interactions with GPIIblIIIa 
showed that ~12 alone can induce at least two yl2 binding sites 
on the receptor, one of which is eliminated by GRGDSP [23]. 
In the present NMR study, the interaction of fibrinogen y- 
chain peptide ~12 with purified GPIIbllIIa has been followed 
in the presence of SDS and increasing concentrations of hex- 
apeptide GRGDSP. Data indicate that GRGDSP induces a 
conformational transition(s) in GPIIb/IIIa-SDS system to gen- 
erate multiple y12 ligand binding states and to modify peptide 
binding affinities. 
2. Methods and materials 
2.1. Peptide synthesis 
Peptides representing amino acid sequences from human fibrinogen 
gamma chain were synthesized as described in ref. [23]. 
2.2. GPIIblIIIa-fibrinogen binding assay 
In order to assess the functionality of purified GPIIb/IIIa [26] before 
and after NMR experiments, an in vitro solid phase purified GPllb/llla 
binding assay using biotinylated fibrinogen was employed as previously 
described [23]. GPIIblIIIa was found to bind parent fibrinogen before 
and after NMR studies. 
2.3. NMR measurements 
Freeze-dried samples for NMR measurements were dissolved in 
H>O/D,O (9: 1). Peptide concentration ranged from 3 mM to 24 mM. 
GPIIb/IIIa receptor concentration was 0.1 mM. pH was adjusted by 
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adding ~1 quantities of NaOD or DC1 to the protein sample. Solution 
conditions were 50 mM sodium phosphate, 2 mM CaCl?, 10 mM SDS, 
pH 6 and 298 K. NOESY and TOCSY (HOHAHA) spectra were 
obtained as described in ref. [23]. All NMR spectra were acquired on 
a Bruker AMX-600 NMR spectrometer. 
3. Results and discussion 
A TOCSY spectrum of ~12 in the presence of purified 
GPIIblIIIa and a 2-fold molar excess of GRGDSP (RGD) is 
shown in Fig. 1. For GRGDSP, sequence-specific assignments 
indicated in this figure were made in the standard way [35] from 
analysis of NOESY and TOCSY spectra. Cis-trms proline 
isomerization [35] of the S5-P6 peptide bond in GRGDSP gives 
rise to two sets of slowly exchanging (600 MHz NMR chemical 
shift time scale) resonances for D4 and S5 as labeled in the 
figure. At this RGD:yl2 ratio, only one set from an original 
two sets of ~12 resonances is observed since RGD effectively 
competes with one ~12 receptor binding species [23]. Reso- 
nance assignments for ~12 are taken from [23]. Due to differen- 
tial line broadening from dynamic exchange between free and 
bound ~12 peptide [23], not all ~12 resonances are observed, 
particularly those belonging to N-terminal residues H400 
through G404. 
Increasing the RGD : ~12 ratio modifies TOCSY spectra sig- 
nificantly, causing additional resonances to appear and original 
resonances to shift, broaden or disappear. This is exemplified 
at ratios of 4: 1 (Fig. 1) and 8: 1 (Fig. 2). Since NOES were 
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mostly absent in NOESY spectra, resonance assignments of 
new cross-peaks could not be made in the standard way [35]. 
Assignments, therefore, were made by spectral comparison and 
spin system identification. Since L402, K406, 4407, and V411 
present unique ~12 spin systems, their identification is un- 
ambiguous. For RGD, R2, S5 and P6 are unique. In any event, 
the attempt here is not to make complete resonance assign- 
ments, but rather to report the effect of RGD on ~12 interac- 
tions with a GPIIb/lIIa&SDS system. Based on these unique 
spin systems, resonances can be assigned to ~12 and RGD 
protons as indicated in Figs. 1 and 2.~12 D410 assignments are 
also based on knowledge of RGD D3 chemical shifts. At an 
RGD:yl2 ratio of 4:1 (Fig. 1), multiple ~12 spin 
systems have appeared. These are most clearly observed for 
V411 where about four valine spin systems can be followed 
from NH through yH, resonances. At higher ratios (see Fig. 
2), these same ~12 states are still present but with near equal 
CXN cross-peak intensities. Notice also that as the RGD:yl2 
ratio is increased to 8: 1, RGD cross-peaks have significantly 
decreased in intensity even though the RGD concentration has 
been increased. This is especially evident with the G3 cross- 
peak. Furthermore, what appears to be three RGD S5 spin 
systems are also indicated by arrows in Fig. 2, suggesting the 
presence of multiple RGD binding states. 
The reversibility of this RGD effect was tested by increasing 
the ~12 concentration to return to RGD: ~12 ratios of 2: 1 and 
1: 1. Fig. 2 presents a TOCSY spectrum at a ratio of 8 : 8 (1: 1) 
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Fig. 1. HOHAHA spectra of ~12 with GPIIblIIIa + GRGDSP. Two HOHAHA spectra are presented showing the aH-NHlupfield region for 
RGD:y12 molar ratios of 2: 1 (left panel) and 4: 1 (right panel). The ~12: GPIIb/IIIa molar ratio is 30: 1 with a GPIIb/IIIa receptor protein 
concentration of 0.1 mM. Spectra were acquired under the same solution conditions: 50 mM sodium phosphate, 2 mM CaCI,, 10 mM SDS, pH 
6 and 298 K. NMR data were acquired and processed as discussed in section 2. Multiple ~12 resonance are labeled as discussed in the text. 
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Fig. 2. 1D HOHAHA slices for ratios of RGD: ~12. Two HOHAHA spectra are presented showing the crH-NH/upfield region for RGD: ~12 molar 
ratios of 8: I (left panel) and 8 : 8 (right panel). The ~12: GPIIbl IIIa molar ratio is 30: 1 with a GPIIb/IIla receptor protein concentration of 0.1 mM. 
Spectra were acquired under the same solution conditions: 50 mM sodium phosphate, 2 mM CaCl,, 10 mM SDS, pH 6 and 298 K. NMR data were 
acquired and processed as discussed in section 2. Multiple ~12 resonance are labeled as discussed in the text. 
showing that the effect of RGD on GPIIb/IIIa ~12 binding is 
not reversed. No reduction in the number of ~12 spin systems 
occurs, and no RGD cross-peaks can be found at their previ- 
ously observed (2: 1 ratio) chemical shift positions. In fact, if 
anything additional y 12 spin systems are observed. This is most 
likely due to increasing y12 peptide concentration as opposed 
to the creation of new states. Five K406, 4407 and V411 spin 
systems are now identifiable (Figure 2) and although seven 
aspartic acid, eight alanine and five glycine spin systems also 
can be observed, these cannot be unambiguously assigned. 
Since these studies have been done with purified GPIIb/IIIa 
(0.1 mM) in the presence of SDS (10 mM), interpretation must 
be approached cautiously. Results, however, do clearly indicate 
the presence of multiple peptide conformational states in slow 
exchange on the NMR chemical shift time scale. Moreover, the 
appearance of these multiple states is a direct consequence of 
the presence of RGD. The crucial question then is the origin 
of these states. Given the high ratio of peptide to receptor that 
is used, experimental artifacts arising from some type of non- 
specific binding are a possibility. However, five observations 
underline the probable specific nature of at least some of these 
interactions: (1) a discrete number of states is observed even 
when the peptide concentration is increased; (2) multiple states 
are not present in the absence of GPIIb/IIIa, i.e. in the presence 
of SDS alone; (3) multiple states are not observed when an eight 
residue fragment of y12 consisting of the last eight C-terminal 
residues is used; (4) the conformational integrity of the receptor 
checked by both circular dichroism (CD) and fibrinogen bind- 
ing assay is unaffected at this SDS : GP IIblIIIa ratio. SDS had 
to be used since GPIIb/IIIa, a membrane protein, is relatively 
insoluble at concentrations required for these experiments 
without some detergent being present. (5) From other studies 
(see section l), both RGD and y12 are known to bind the 
receptor at multiple sites. 
If peptide were tightly bound to GPIIblIIIa with a slow off 
rate, then its NMR signal should disappear for a complex of 
220 kDa at a concentration of 0.1 mM. On the other hand, if 
there were a rapid equilibrium between free and bound peptide, 
then chemical shifts should represent a weighted average be- 
tween free and bound forms [6,21,24]. Neither scenario pre- 
cisely explains the NMR observations. At higher RGD concen- 
trations, RGD cross-peak behavior may fit the first scenario 
since resonances appear to be highly broaden and disappear. 
For ~12, however, the only viable explanation for the appear- 
ance of multiple binding states appears to be that GPIIblIIIa 
in the presence of SDS forms a system which mediates slow 
exchange among multiple peptide conformational states. SDS 
is known to form micelles under present conditions [33] and is 
most likely associating with the receptor, prehaps like an artifi- 
cial membrane. It is conceivable that peptides interact with 
GPIIb/IIIa through an SDS interface which acts to slow down 
exchange among receptor-dissociated peptide states. 
Since RGD only acts this way in the presence of GPIIb/IIIa 
whose integrity is maintained at this SDS concentration, RGD 
must be inducing changes in the receptor. Du et al. [ 131 have 
stated that RGDIyl2 peptide ligands can activate receptor- 
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ligand binding by inducing conformational changes in GPllbl 
IIIa, and in several studies, it has been hypothesized that fibrin- 
ogen binding to GPIIblIIIa may proceed by initial recognition 
of an RGD-like sequence, recognition-induced conformational 
change, and then additional high affinity ligand-receptor inter- 
action(s) [15]. At this level of analysis, the precise nature of 
these changes observed in our system remains unknown. Possi- 
bilities include an increased number of 712 bound state at a 
single or a few binding sites, a combination of multiple bound 
states at multiple sites, or multiple independent binding sites. 
Some non-specific binding also can not be excluded. Further- 
more, although the meaning of these results in terms of in vivo 
yl2/RGD GPIIb/IIIa integrin receptor-fibrinogen interactions 
and platelet cell adhesion also remains unclear, the creation of 
multiple ~12 binding sites on GPIIblIIIa may facilitate fibrino- 
gen y-chain interactions with the platelet cell surface receptor. 
The C-terminal segment in a longer y-chain peptide 385-411 
has been found to be highly flexible [22] allowing for consider- 
able sampling of conformational space such that any number 
of structures may be selected on binding to the receptor. 
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